"We're particularly excited about Dototate, a peptide that binds to somatostatin receptors," said Jonathan McConathy, MD, PhD, Director of the Division of Molecular Imaging and Therapeutics at UAB.
In the past, tumors were often treated based on where they first presented. In the lung, they were treated as lung cancer. In the prostate, odds were that a prostate cancer protocol would offer the greatest hope for a cure.
Does PSA-based screening for prostate cancer do more harm than good? While the USPSTF has released final recommendations for routine screening, the answer really remains an individualized decision.
During a man's lifetime, odds are one in seven that he be diagnosed with prostate cancer. If it's a slower growing form detected in later years, he may live out a normal life span and die with it, but not from it.
You may not be getting all you can out of your browsing experience
and may be open to security risks!
Consider upgrading to the latest version of your browser or choose on below: